Ipratropium formulation for pulmonary inhalation
US6455028B1 · kind B1 · utility
23Cited by
12References
67Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 23, 2001 |
| Grant date | Sep 24, 2002 |
| Priority date | — |
| Expiry date | Apr 23, 2021 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P11/08
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Pharmaceutical aerosol formulations are provided comprising substantially nonacicular particles of a bronchodilator selected from the group consisting of ipratropium and pharmacologically acceptable salts, solvates, hydrates, esters and isomers thereof. The described formulations include a propellant selected from the group consisting of a fluorocarbon propellant, a hydrogen-containing fluorocarbon propellant, and mixtures thereof. The formulations are substantially free of both surfactant and solvent. Methods of use and drug delivery devices are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.